Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 97

Sort by

Sort Order Select

Journal Articles

Single-Cell Multi-Omics Reveals Type-2 Functionality in Maintaining CAR T Cell Longevity Associated with 8-Year Leukemia Remission

Zhiliang Bai, Bing Feng, Susan E. Mcclory, Caroline Diorio, Ziran Zhao, Li Tang, J. Joseph Melenhorst, Carl June, Stephan Grupp, Rong Fan

Blood (2023) 142 (Supplement 1): 352.

https://doi.org/10.1182/blood-2023-179480

Published: 2023

Journal Articles

Signaling Role of Viral Protein Motif and Its Application in CAR T Cell Therapy

Kunho Chung, Wooram Jung, Jae U Jung, J. Joseph Melenhorst

Blood (2023) 142 (Supplement 1): 4815.

https://doi.org/10.1182/blood-2023-186305

Published: 2023

Journal Articles

T-Cell Dysfunction in CLL Can be Alleviated By Blocking Sialic Acid-Binding Ig-like Lectin 10 (Siglec-10) Ligation

Jaco A.C. Van Bruggen, Fleur Peters, Joanne M. Rietveld, Gaspard Cretenet, Joseph Melenhorst, Eric Eldering, Arnon P. Kater

Blood (2022) 140 (Supplement 1): 12688–12689.

https://doi.org/10.1182/blood-2022-168800

Published: 2022

Journal Articles

Co-Stimulatory Signaling Boosts CAR T Cell Efficacy Against CLL

Ziran Zhao, McKensie Collins, Clare Sun, Adrian Wiestner, J. Joseph Melenhorst

Blood (2022) 140 (Supplement 1): 10255–10256.

https://doi.org/10.1182/blood-2022-158614

Published: 2022

Journal Articles

Functional Disruption of TET2-Mediated Cytosine Oxidation in CAR-T Cells Using IDH1 Neomorph

Kunho Chung, Jie Xu, Yaroslav Kaminskiy, Hongxing Sun, Min-Soo Kim, Christopher Petucci, Tong Wang, Rahul M Kohli, J. Joseph Melenhorst

Blood (2022) 140 (Supplement 1): 628–629.

https://doi.org/10.1182/blood-2022-159517

Published: 2022

Journal Articles

Do CARs finally hit the CLL road?

Arnon P. Kater, J. Joseph Melenhorst

Blood (2022) 139 (12): 1775–1776.

https://doi.org/10.1182/blood.2021014492

Published: 2022

Journal Articles

Chronic Lymphocytic Leukemia Actively Induces T-Cell Dysfunction By Contact-Dependent Signaling Via CD24 and CD52

Jaco A. C. Van Bruggen, Fleur Peters, Gaspard Cretenet, J. Joseph Melenhorst, Eric Eldering, Arnon P. Kater

Blood (2021) 138 (Supplement 1): 3714.

https://doi.org/10.1182/blood-2021-152495

Published: 2021

Journal Articles

Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells

Blood (2021) 138 (Supplement 1): 166.

https://doi.org/10.1182/blood-2021-152664

Published: 2021

Journal Articles

Comprehensive Secretome Profiling Elucidates Novel Disease Biology and Identifies Pre-Infusion Candidate Biomarkers to Predict the Development of Severe Cytokine Release Syndrome in Pediatric Patients Receiving CART19

Blood (2021) 138 (Supplement 1): 167.

https://doi.org/10.1182/blood-2021-149477

Published: 2021

Journal Articles

Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells

Natalie F. Uy, MD, Edward Pequignot, Noelle V. Frey, MD, Megan Davis, PhD, Elizabeth O. Hexner, MD, Stephen J. Schuster, MD, Saar Gill, MD PhD, Alison W. Loren, MD, Stephan A Grupp, MD PhD, J. Joseph Melenhorst, PhD, Simon F Lacey, PhD, Joseph A Fraietta, PhD, Joan Gilmore, BS, Lester Lledo, RN,NP, Wei-Ting Hwang, PhD, Don L. Siegel, MD PhD, Bruce L Levine, PhD, Carl H June, MD, David L. Porter, MD

Blood (2020) 136 (Supplement 1): 30–32.

https://doi.org/10.1182/blood-2020-141224

Published: 2020

Journal Articles

B-CLL Mediated Resistance to CAR T Cell Therapy Via Insufficient Activation Is CAR-Independent

McKensie Collins, BS, Weimin Kong, PhD, Inyoung Jung, BS, Stefan M Lundh, BS, J. Joseph Melenhorst, PhD

Blood (2020) 136 (Supplement 1): 44.

https://doi.org/10.1182/blood-2020-137638

Published: 2020

Journal Articles

Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome

Qian Zhang, Elena J. Orlando, Hong Y. Wang, Agata M. Bogusz, Xiaobin Liu, Simon F. Lacey, Honore T. Strauser, Selene Nunez-Cruz, Reza Nejati, Paul Zhang, Sarah Brooks, Christopher Watt, J. Joseph Melenhorst, Carl H. June, Stephen J. Schuster, Mariusz A. Wasik

Blood (2020) 136 (17): 1980–1983.

https://doi.org/10.1182/blood.2020005123

Published: 2020

Includes: Supplemental data

Journal Articles

CAR-T and ibrutinib vs CLL: sequential or simultaneous?

Arnon P. Kater, J. Joseph Melenhorst

Blood (2020) 135 (19): 1611–1612.

https://doi.org/10.1182/blood.2020005362

Published: 2020

Journal Articles

A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor–positive cells

Marco Ruella, David M. Barrett, Olga Shestova, Jessica Perazzelli, Avery D. Posey, Jr, Seok Jae Hong, Miroslaw Kozlowski, Simon F. Lacey, J. Joseph Melenhorst, Carl H. June, Saar I. Gill

Blood (2020) 135 (7): 505–509.

https://doi.org/10.1182/blood.2019001859

Published: 2020

Includes: Supplemental data

Journal Articles

Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1863.

https://doi.org/10.1182/blood-2019-131515

Published: 2019

Journal Articles

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

Meng Wang, BS, Iulian Pruteanu, PhD, Adam D. Cohen, MD, Alfred L. Garfall, MD, Lifeng Tian, PhD, Simon F Lacey, PhD, Joseph A Fraietta, PhD, Jennifer Brogdon, PhD, Megan Davis, PhD, Vanessa E. Gonzalez, Bruce L Levine, PhD, Don L. Siegel, MD PhD, Michael C. Milone, Edward A. Stadtmauer, MD FACP, Carl H June, MD, J. Joseph Melenhorst, PhD

Blood (2019) 134 (Supplement_1): 1909.

https://doi.org/10.1182/blood-2019-122396

Published: 2019

Journal Articles

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Blood (2019) 134 (Supplement_1): 49.

https://doi.org/10.1182/blood-2019-122374

Published: 2019

Journal Articles

A Failure to Start: Aborted Activation of CAR T Cells in Chronic Lymphocytic Leukemia

McKensie Collins, BS, Weimin Kong, PhD, Inyoung Jung, BS, Meng Wang, BS, Stefan M Lundh, BS, Carl H June, MD, J. Joseph Melenhorst, PhD

Blood (2019) 134 (Supplement_1): 681.

https://doi.org/10.1182/blood-2019-122063

Published: 2019

Journal Articles

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Blood (2019) 134 (Supplement_1): 622.

https://doi.org/10.1182/blood-2019-122513

Published: 2019

Journal Articles

Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8 + T cells and impede CAR T-cell efficacy

Jaco A. C. van Bruggen, Anne W. J. Martens, Joseph A. Fraietta, Tom Hofland, Sanne H. Tonino, Eric Eldering, Mark-David Levin, Peter J. Siska, Sanne Endstra, Jeffrey C. Rathmell, Carl H. June, David L. Porter, J. Joseph Melenhorst, Arnon P. Kater, Gerritje J. W. van der Windt

Blood (2019) 134 (1): 44–58.

https://doi.org/10.1182/blood.2018885863

Published: 2019

Includes: Supplemental data

NARROW

Single-Cell Multi-Omics Reveals Type-2 Functionality in Maintaining CAR T Cell Longevity Associated with 8-Year Leukemia Remission

Signaling Role of Viral Protein Motif and Its Application in CAR T Cell Therapy

T-Cell Dysfunction in CLL Can be Alleviated By Blocking Sialic Acid-Binding Ig-like Lectin 10 (Siglec-10) Ligation

Co-Stimulatory Signaling Boosts CAR T Cell Efficacy Against CLL

Functional Disruption of TET2-Mediated Cytosine Oxidation in CAR-T Cells Using IDH1 Neomorph

Do CARs finally hit the CLL road?

Chronic Lymphocytic Leukemia Actively Induces T-Cell Dysfunction By Contact-Dependent Signaling Via CD24 and CD52

Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells

Comprehensive Secretome Profiling Elucidates Novel Disease Biology and Identifies Pre-Infusion Candidate Biomarkers to Predict the Development of Severe Cytokine Release Syndrome in Pediatric Patients Receiving CART19

Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells

B-CLL Mediated Resistance to CAR T Cell Therapy Via Insufficient Activation Is CAR-Independent

Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome

CAR-T and ibrutinib vs CLL: sequential or simultaneous?

A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor–positive cells

Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

A Failure to Start: Aborted Activation of CAR T Cells in Chronic Lymphocytic Leukemia

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8 + T cells and impede CAR T-cell efficacy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only